Myeloma Patients Europe

09/06/2026

More flexibility on the horizon for myeloma patients in Europe!

The European Commission has approved a subcutaneous (under the skin) formulation of isatuximab (Sarclisa®), covering all myeloma indications already approved for the intravenous version.

What makes this approval particularly notable is the CirCLIQ® on-body injector, a small wearable device that delivers the treatment automatically under the skin. It is the first anticancer treatment in the EU approved for delivery via an on-body injector and could allow treatment to take place in outpatient settings or even at home, reducing the time patients spend in hospital or travelling to it.

Read our full article here: https://www.mpeurope.org/european-commission-approves-subcutaneous-isatuximab-for-the-treatment-of-multiple-myeloma/

| Learn more about myeloma and AL amyloidosis at the website.

08/06/2026

Looking to travel this summer?

Can you travel safely when living with myeloma?

In this video, Dr Charlotte Pawlyn shares practical guidance for patients managing myeloma while travelling.

https://f.mtr.cool/loxbrgyawf

Can you travel with multiple myeloma?People living with myeloma s...

08/06/2026

This week MPE is attending in Stockholm, Sweden.

Follow us for daily updates, research highlights and the latest from this year's sessions and if you want myeloma news delivered straight to your inbox, sign up to the MPE Newsletter for monthly updates, research and resources.

Sign up here: https://f.mtr.cool/dmzyebuctl

03/06/2026

Nutrition during myeloma treatment matters — but it is not always easy to eat well when side effects get in the way.

A few helpful tips:
- Eat little and often if large meals feel difficult.
- Carry healthy snacks when you leave the house.
- Stay well hydrated — aim for 1.5 to 2 litres of fluid a day.
- Ask your team about a referral to a dietitian if you are unsure.

Small changes can make a real difference to your energy and wellbeing.

01/06/2026

Approximately 12–15% of myeloma patients may develop symptomatic AL amyloidosis. You can learn more about AL amyloidosis on our website or in our patient guide.

27/05/2026

Managing uncertainty in myeloma isn't talked about enough — the anxiety of waiting for what's next.

Waiting for results, waiting to see if treatment is working, waiting for the next appointment. For many people living with myeloma, the uncertainty between appointments can be just as difficult to manage as the treatment itself.

Contact your local myeloma organisation if you feel you need more support with this https://www.mpeurope.org/about-mpe/our-members/

25/05/2026

Do you feel like your myeloma treatment is not working for you?

Only you know your body. Advocating for yourself is one of the most important things you can do.

Contact your team if something has changed, without waiting for your next appointment.

Ask them to explain your latest results. Is your M-protein or free light chain level rising?

If you feel you are not being heard, ask for a referral to a specialist myeloma centre or a second opinion.

20/05/2026

Today is

Clinical trials have brought us the treatments that are transforming myeloma care today. Thank you to all the patients, carers, clinicians and researchers across Europe and beyond who take part in a clinical trial and make progress possible.

The MPE Clinical Trial Navigator helps patients, carers and healthcare professionals find trials across Europe, covering myeloma, smouldering myeloma, MGUS and AL amyloidosis.

Explore clinical trials happening right now: https://navigator.mpeurope.org/en/trials/find-trial

18/05/2026

Smouldering myeloma is an early, asymptomatic form of myeloma that can progress to active myeloma?

In most cases, it does not need treatment, but diagnosed patients will be monitored regularly.

Learn more: https://f.mtr.cool/uxqezrolvd

15/05/2026

We are excited to share that we've launched a new five-year Research Strategy — and this month's newsletter is where you can read all about it.

Our Research Strategy sets out four priority themes for 2026–2030.

Read the newsletter here to find out more: https://f.mtr.cool/tfogcicgge

Not yet subscribed? Sign up at https://f.mtr.cool/hjbffqzecj to receive future editions directly to your inbox.

This form collects the data shown below and will be included in our Mailchimp distribution list only for updating purposes on our programs and activities. Check out our privacy policy to see how we protect and manage your submitted data.